Mammalian Cell Culture Media Patents: Leaders & Trends 2026
Mammalian cell culture media formulation patents: who holds the claim space and where it is still open
Concentrated but not locked up. The leader holds 711 records, yet the top 5 combined account for only 15.4% of the 12,825 records in scope — a long tail of single- and few-filing entrants sits beneath a handful of large incumbents. Filings hit 356 in 2017, the high point of the series. Using the most recent years that can be treated as complete, 2021's 239 filings fell to 147 by 2024 — a 38% decline over three years. Because publication lags filing by roughly 18 months, 2025 and 2026 figures will fill in further and should not be read as a continued slide.
- 1GENENTECH INC5.5%
- 2AMGEN INC3.2%
- 3HUMAN GENOME SCI INC2.7%
- 4INCYTE CORP2.4%
- 5REGENERON PHARMACEUTICALS INC1.6%
See the full mammalian cell culture media formulation analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in mammalian cell culture media formulation?
The dataset’s leading assignee holds 711 records, well ahead of the field, with the fifth-ranked assignee at 211 and the tenth at 167. However, the top 5 combined account for only 15.4% of the 12,825 records in scope, and the top 10 for 22.9%, so the field is far from a two- or three-way contest. A long tail of assignees with a handful of filings each makes up the majority of the corpus.
Is patent filing in cell culture media formulation slowing down?
Filings peaked at 356 in 2017 and, across the most recent years that can be treated as complete, fell from 239 in 2021 to 147 in 2024 — a 38% decline. That is a real multi-year pullback in complete-year data. The most recent one to two years in the raw trend appear lower still, but that reflects roughly 18 months of publication lag rather than a further collapse in filing activity.
Which patent classes cover the most cell culture media formulation IP?
C12N (microorganisms and genetic engineering) covers 94.0% of the 12,825 records in scope, making it by far the densest class. C07K (peptides & proteins) and A61K (medicinal preparations) each cover about 48.9%, and C12Q (enzyme/DNA measurement) covers 38.0%. Because a single record can carry multiple IPC classes, these percentages add up to well over 100% and should not be summed.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Mammalian Cell Culture Media Formulation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.